Ricerca pubblicata

Noi di Bedrocan miriamo a colmare il divario presente tra le esigenze dei pazienti relative alla cannabis e gli standard qualitativi della medicina moderna. Questo è il punto focale della nostra ricerca. Creiamo forti partnership di ricerca in ambito accademico e privato e conduciamo studi indipendenti. In definitiva condividiamo ciò che apprendiamo.

Indicazioni

Studi clinici, controllati con placebo e in doppio cieco, sono il gold standard attuale per determinare l’efficacia e la sicurezza dei medicinali. Tali studi sono molto costosi e richiedono molto tempo, ma considerando i vantaggi rispetto ai rischi, aiutano a decidere dove e quando l’uso di un nuovo trattamento medico è appropriato e responsabile.

Clicca qui per un osservazione dei prodotti di Bedrocan usati negli esseri umani.

Tema Nazione Organizzazioni Prodotto
Fibromialgia e/o dolore cronico Paesi Bassi Leids Universitair Medisch Centrum (LUMC) Bedrocan
Cure palliative pazienti con cancro Australia St Vincent’s Sacred Heart Health Service and Calvary Mater Hospital Bedrobinol

Forme amministrative

I cannabinoidi operano in maniera diversa in relazione alla loro modalità di assunzione (ad esempio ingeriti in un olio o inalati con un vaporizzatore). Con il nostro lavoro miriamo a comprendere queste differenze. Studiamo le modalità di assunzione preferite (senza fumare) e ciò che le persone fanno oggi (fumare). Oltre a quanto segue, abbiamo svolto la ricerca che ha permesso l’approvazione del vaporizzatore Volcano Medic® come dispositivo medico per l’inalazione di cannabis.

Ricera Autore Pubblicazione Anno
Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Hazekamp J. Pharm. Sci.; 95(6): 1308-1317 2006
Cannabis tea revisited: A systematic evaluation of the cannabinoid composition of cannabis tea. Hazekamp Journal of Ethnopharmacology; 113, 85–90 2007
Cannabis smoke condensate III: The cannabinoid content of vaporised Cannabis sativa. Pomahacova Inhalation Toxicology; 21(13): 1108–1112 2007
Effect of intrapulmonary tetrahydrocannabinol administration in humans Zuurman, Hazekamp J Psychopharmacol.; 22(7): 707-716 2008
Cannabis Smoke Condensate I: The Effect of Different Preparation Methods on Tetrahydrocannabinol Levels Van der Kooy Inhalation Toxicology; 20:9, 801-804 2008
Cannabis Smoke Condensate II: Influence of Tobacco on Tetrahydrocannabinol Levels Van der Kooy Inhalation Toxicology; xx:1–4 2008
Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor Fischedick Chem. Pharm. Bull.; 58(2): 201-207 2010
Plasma and urine profiles of Δ9-tetrahydrocannabinol and its metabolites 11-hydroxy-Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes Brenneisen Analytical and Bioanalytical Chemistry; 396(7): 2493-2502 2010
Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine Romano, Hazekamp Cannabinoids; 1(1): 1-11 2013
The medicinal use of cannabis and cannabinoids–an international cross-sectional survey on administration forms Hazekamp, Ware, Muller-Vahl, Abrams, Grotenhermen J Psychoactive Drugs; 45(3): 199-210 2013
A protocol for the delivery of cannabidiol (CBD) and combined CBD and Δ9-tetrahydrocannabinol (THC) by vaporisation Solowij, Broyd, Van Hell, Hazekamp BMC Pharmacology and Toxicology, 15:58 2014
Evaluating the Effects of Gamma-Irradiation for Decontamination of Medicinal Cannabis Hazekamp Frontiers in Pharmacology; 7, article 108  2016

Ricerca social

La cannabis è utilizzata da molte migliaia di persone per trattare sintomi relativi a uno stato di salute, spesso al di fuori dalle cure di un medico. Nel nostro sforzo di cercare un legame tra il laboratorio e le realtà dell’utilizzo da parte del paziente conduciamo studi su comportamenti e preferenze degli utilizzatori di cannabis. Raccogliamo informazioni su dosaggio, indicazioni, forme di assunzione, varietà di cannabis e altro.

Ricera Autore Pubblicazione Anno
An evaluation of the quality of medicinal grade cannabis in the Netherlands. Hazekamp Cannabinoids; 1(1):1-9 2006
How accurate is potency testing? Gieringer, Hazekamp O’Shaughnessy’s. Autumn: 17 2011
The medicinal use of cannabis and cannabinoids–an international cross-sectional survey on administration forms. Hazekamp, Ware, Muller-Vahl, Abrams, Grotenhermen J Psychoactive Drugs; 45(3): 199-210 2013
The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Hazekamp, Heerdink Eur J Clin Pharmacol.; 69(8):1575-80 2013
Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis Brunt, Van Genugten, Höhner, Van de Velde, Niesink Journal of Clinical Psychopharmacology & Volume 34, Number 3 2014

Chimica della cannabis

Lavoriamo per comprendere esattamente la composizione della nostra cannabis e di quella che le persone utilizzano quotidianamente. Le nostre varietà diverse di cannabis sono finalizzate alla ricerca e interamente standardizzate, pertanto i risultati possono essere confrontati con molti studi utilizzando le stesse varietà.

Ricera Autore Pubblicazione Anno
Preparative isolation of cannabinoids from Cannabis sativa by centrifugal partition chromatography. Hazekamp et al. Journal of Liquid Chromatography & Related Technologies; 27(15): 2421-2439. 2004
Quantitative analysis of cannabinoids from Cannabis sativa Using 1H-NMR. Hazekamp Chem. Pharm. Bull.; 52(6): 718-721 2004
Chromatographic and spectroscopic data of cannabinoids from Cannabis sativa L. Hazekamp Journal of Liquid Chromatography & Related Technologies; 28: 2361-2382 2005
Structure elucidation of the tetrahydrocannabinol complex with randomly methylated beta-cyclodextrin. Hazekamp Eur. Journal Pharm. Science; 29: 340-347 2006
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. De Jong The Oncologist 12: 291–300 2007
Synthesis and spectroscopic characterization of cannabinolic acid. Bastola, Hazekamp Planta Medica; 73: 1-3 2007
A qualitative and quantitative HPTLC densitometry method for the analysis of cannabinoids in Cannabis sativa L. Fischedick, Hazekamp. Phytochemical Analysis; 20: 421–426  2009
Metabolic fingerprinting of Cannabis sativa L., Cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Fischedick, Hazekamp Phytochemistry; 71(17-18): 2058-2073  2010
Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor. Fischedick Chem. Pharm. Bull.; 58(2): 201-207  2010
How accurate is potency testing? Gieringer, Hazekamp O’Shaughnessy’s. Autumn 2011: 17  2011
Cannabis – From cultivar to chemovar. Hazekamp, Fischedick Drug Testing and Analysis; 4: 660-667 2012
That which we call Indica, by any other name would smell as sweet. Erkelens, Hazekamp Cannabinoids 2014; 9(1): 9-15  2014
From cultivar to chemovar II – A metabolomics approach to cannabis classification. Hazekamp Cannabis and Cannabinoid Research Volume 1.1  2016

Le recensioni

Ricera Autore Pubblicazione Anno
Review on clinical studies with cannabis and cannabinoids 2005-2009. Hazekamp, Grotenhermen Cannabinoids; 5: 1-21 2010
Chemistry of cannabis. Hazekamp et al. In: Comprehensive Natural Products II Chemistry and Biology; Mander L, Lui HW, Eds. Elsevier, Oxford 2010; volume 3: 1033–1084 2010
Modulation of cognitive and emotional processing by cannabidiol: the role of the anterior cingulate cortex. Kowal, Hazekamp Frontiers in Human Neuroscience; 7: 147. 2013
Self-medication with cannabis. Hazekamp, Pappas In: Handbook of Cannabis. Pertwee R, Ed. Oxford University Press, Oxford; chapter 17  2014
Cannabis and creativity: Highly potent cannabis impairs divergent thinking in regular cannabis users. Kowal, Hazekamp et al. Psychopharmacology (Berl); 232:1123–1134 2014
Dose-dependent effects of cannabis on the neural correlates of error monitoring in frequent cannabis users. Kowal, Hazekamp et al. European Neuropsychopharmacology; volume 25, Issue 11, Pages 1943–1953 2015
Review on clinical studies with cannabis and cannabinoids 2010-2014. Kowal, Hazekamp, Grotenhermen Cannabinoids; 11 (special issue):1-18 2016
Thinking high: The impact of cannabis on human cognition. Kowal 2016

Human Research Using Bedrocan Products

Autore Autore Pubblicazione Anno
High-Potency Marijuana Impairs Executive Function and Inhibitory Motor Control Ramaekers et al. Neuropsychopharmacology 31, 2296–2303 2006
Cognition and motor control as a function of delta-9-THC concentration in serum and oral fluid: Limits of impairment Ramaekers et al. Drug and Alcohol Dependence 85, 114–122 2006
Dubbel-blind, gerandomiseerd, placebogecontroleerd, 4-weg gekruist onderzoek naar de farmacokinetiek en effecten van cannabis Mensinga et al. RIVM rapport 267002001/2006 2006
Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel Engels et al. The Oncologist; 12:291–300 2007
Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC Hunault et al. Journal of Psychopharmacology 201:171–181 2008
Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users Ramaekers et al. Journal of Psychopharmacology 23: 266 2009
Plasma and urine profiles of delta-9-tetrahydrocannabinol and its metabolites 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes Brenneisen et al. Analytical and Bioanalytical Chemistry 2010
Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users Ramaekers et al. Psychopharmacology 214:391–401 2011
Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication Theunissen et al. Psychopharmacology 220:341–350 2012
Single doses of THC and cocaine decrease proficiency of impulse control in heavy cannabis users Van Wel et al. British Journal of Pharmacology 170 1410–1420 2013
Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint Fabritius et al. Anal Bioanal Chem 405:9791–9803 2013
Weed or Wheel! fMRI, Behavioural, and Toxicological Investigations of How Cannabis Smoking Affects Skills Necessary for Driving Battistella et al. PLOS ONE, Volume 8, Issue 1, e52545 2013
The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study Eisenberg et al. Journal of Pain & Palliative Care Pharmacotherapy; 28:216–225 2014
Acute subjective effects after smoking joints containing up to 69 mg delta-9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial Hunault Psychopharmacology 2014
Acute effects of cocaine and cannabis on reversal learning as a function of COMTand DRD2 genotype Spronk et al. Psychopharmacology 2015
Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity Van Wel et al. Journal of Psychopharmacology, Vol. 29(3) 324–334 2015
Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans Theunissen et al. Psychopharmacology, 232:343–353  2015
Opposite effects of cannabis and cocaine on performance monitoring Spronk et al. European Neuropsychopharmacology  2016
Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes Ramaekers et al. Brain Imaging and Behavior, 10:1254–1263 2016
Cannabis and tolerance: acute drug impairment as a function of cannabis use history Ramaekers et al. Sci. Rep. 6, 26843 2016
Subjective aggression during alcohol and cannabis intoxication before and after aggression exposure De Sousa et al. Psychopharmacology (2016) 233:3331–3340 2016
Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses Lawn et al. Psychopharmacology, 233:3537–3552 2016
Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males Mokrysz et al. Citation: Transl Psychiatry, 6, e961 2016
Explorative Placebo-Controlled Double-Blind Intervention Study with Low Doses of Inhaled Delta-9-Tetrahydrocannabinol and Cannabidiol Reveals No Effect on Sweet Taste Intensity Perception and Liking in Humans De Bruijn et al. Cannabis and Cannabinoid Research Volume 2.1 2017

Per maggiori informazioni, per favore download la pubblicazione Introduzione alla cannabis medicinale di ill Dr. Arno Hazekamp.

First Name *

Last Name *

Your Email *

Company Name

Country

Profession

Subscribe to Newsletter *

* required

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.

Start typing and press Enter to search